KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Non-cash Items: 2013-2025

Historic Non-cash Items for Xenon Pharmaceuticals (XENE) over the last 12 years, with Sep 2025 value amounting to $6.4 million.

  • Xenon Pharmaceuticals' Non-cash Items rose 7.10% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year increase of 7.10%. This contributed to the annual value of $111.2 million for FY2024, which is 44.43% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Non-cash Items stood at $6.4 million for Q3 2025, which was up 1.70% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Non-cash Items registered a high of $200.1 million during Q4 2023, and its lowest value of $2.8 million during Q1 2021.
  • For the 3-year period, Xenon Pharmaceuticals' Non-cash Items averaged around $23.2 million, with its median value being $5.9 million (2024).
  • In the last 5 years, Xenon Pharmaceuticals' Non-cash Items soared by 246.00% in 2021 and then tumbled by 97.04% in 2024.
  • Xenon Pharmaceuticals' Non-cash Items (Quarterly) stood at $105.4 million in 2021, then surged by 39.67% to $147.2 million in 2022, then skyrocketed by 35.94% to $200.1 million in 2023, then tumbled by 97.04% to $5.9 million in 2024, then increased by 7.10% to $6.4 million in 2025.
  • Its last three reported values are $6.4 million in Q3 2025, $6.3 million for Q2 2025, and $6.5 million during Q1 2025.